<?xml version="1.0" encoding="UTF-8"?>
<p>AEs were evaluated throughout the treatment period and for 30 days after the final dose of study treatment and graded according to the National Cancer Institute's Common Terminology Criteria for AEs, version 4·03 (
 <ext-link ext-link-type="uri" xlink:href="https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</ext-link>). Patients reported their experience of neurotoxicity using the Functional Assessment of Cancer Therapy/Gynecology Oncology Group Neurotoxicity (FACT/GOG‐Ntx) questionnaire (Calhoun 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0006" ref-type="ref">2003</xref>), which was completed on day 1 of every treatment cycle and at the end‐of‐treatment visit.
</p>
